Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Interest & Investment Income (2018 - 2025)

Historic Interest & Investment Income for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $6.9 million.

  • 10x Genomics' Interest & Investment Income rose 5288.38% to $6.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $20.0 million, marking a year-over-year increase of 590.6%. This contributed to the annual value of $20.0 million for FY2025, which is 590.6% up from last year.
  • As of Q4 2025, 10x Genomics' Interest & Investment Income stood at $6.9 million, which was up 5288.38% from $5.2 million recorded in Q3 2025.
  • 10x Genomics' 5-year Interest & Investment Income high stood at $6.9 million for Q4 2025, and its period low was $49000.0 during Q3 2021.
  • For the 5-year period, 10x Genomics' Interest & Investment Income averaged around $3.1 million, with its median value being $4.0 million (2023).
  • Per our database at Business Quant, 10x Genomics' Interest & Investment Income plummeted by 9620.64% in 2021 and then soared by 564489.8% in 2022.
  • Over the past 5 years, 10x Genomics' Interest & Investment Income (Quarter) stood at $49000.0 in 2021, then surged by 5644.9% to $2.8 million in 2022, then surged by 63.98% to $4.6 million in 2023, then decreased by 2.34% to $4.5 million in 2024, then surged by 52.88% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q4 2025, $5.2 million for Q3 2025, and $4.3 million during Q2 2025.